The future of engineered cell therapies starts here.
Power your research with our patented, non-viral technology to rapidly deliver small molecules, nucleic acids, proteins, and gene-editing complexes to immune cells while yielding millions to billions of high-quality cells with preserved cell viability and function.
Hydropore™
Hydropore™ is a simple, scalable, and efficient way to accelerate the discovery, development, and manufacturing of engineered cell therapies such as T-cell immunotherapies. This novel, non-viral technology utilizes the power of microfluidic vortex shedding (µVS) to rapidly deliver small molecules, nucleic acids, proteins, and gene-editing complexes to immune cells in a matter of seconds, yielding millions to billions of high-quality cells with negligible impact to cell viability and function. Hydropore™ bypasses the challenges and limitations of viral transduction and traditional transfection via electroporation, allowing companies to accelerate their research goals from discovery to manufacturing.
Order Hydropore™ for knockout and knock-in genome editing now!
Hydropore™ is developed in a regulatory-ready manner and currently available for Research Use Only. A clinical system will be regulated as a tool for biologics manufacturing. Both systems are developed in an ISO 13485-compliant manner and all materials in the flow path are medical-grade or USP Class VI implantable-grade. Hydropore™ is also suitable for high-throughput pooled screening of small volumes.
Stay up-to-date with our latest news, updates & research at Indee Labs.
In the News
